Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence

Inserra, Antonio; Piot, Alexandre; De Gregorio, Danilo; Gobbi, Gabriella

doi:10.1007/s40263-023-01008-5

Cited by 7 publications

(3 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All things considered, a potential rationale for the usage of psychedelics in DS will be developed in the next sections. There are several pre-clinical and clinical indications that psychedelics (e.g., LSD) may have a therapeutic role in alleviating anxiety (see, for a recent review, Inserra et al, 2023 ). Thus, by reducing anxiety in DS, psychedelics may modulate activity in overactivated (or underactivated) systems, thereby reducing difficulties and allowing “easier” control (i.e., with limited interferences) of speech-motor systems ( Alm, 2014 ; Jackson et al, 2022 ; Orpella et al, 2024 ).…”

Section: Interactions Between Atypical Neural Systems In Ds and Assoc...mentioning

confidence: 99%

“…By means of fMRI/EEG co-registration, they demonstrated that increased “entropy” correlated with decreased alpha power (compare with Annerud Awrohum, 2021 ), and also showed that regions with the densest expression of 5-HT2A receptors (PET data) were the most affected by the psychedelic compound ( Timmermann et al, 2023 ). In this regard, animal models suggest that the effect of psychedelics (e.g., LSD) may be mediated by brain regions and networks that are strongly involved in the control of anxiety (DMN, prefrontal cortex-amygdala circuits and cortico-striato-thalamo-cortical networks; Inserra et al, 2023 ). Even if more translational research is required to understand the exact mechanisms involved, several studies have demonstrated the anti-anxiety effects of LSD in animals, as well as also reported in clinical trials (compare with Holze et al, 2023 ).…”

Section: Psychedelic Drugs: Possible Brain Mechanismsmentioning

confidence: 99%

See 1 more Smart Citation

Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Pasculli,

Busan,

Jackson

et al. 2024

Front. Hum. Neurosci.

Self Cite

View full text Add to dashboard Cite

Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS -specifically, brain metabolic and default mode/social-cognitive networks (DMN/SCN) anomalies- arguing that psychedelic compounds might be considered and investigated (e.g., in randomized clinical trials) for treatment of DS. The neural background of DS is likely to be heterogeneous, and some contribution from genetically determinants of metabolic deficiencies in the basal ganglia and speech-motor cortical regions are thought to play a role in appearance of DS symptoms, which possibly results in a cascade of events contributing to impairments in speech-motor execution. In persistent DS, the difficulties of speech are often linked to a series of associated aspects such as social anxiety and social avoidance. In this context, the SCN and DMN (also influencing a series of fronto-parietal, somato-motor, and attentional networks) may have a role in worsening dysfluencies. Interestingly, brain metabolism and SCN/DMN connectivity can be modified by psychedelics, which have been shown to improve clinical evidence of some psychiatric conditions (e.g., depression, post-traumatic stress disorder, etc.) associated with psychological constructs such as rumination and social anxiety, which also tend to be present in persistent DS. To date, while there have been no controlled trials on the effects of psychedelics in DS, anecdotal evidence suggests that these agents may have beneficial effects on stuttering and its associated characteristics. We suggest that psychedelics warrant investigation in DS.

show abstract

Section: Interactions Between Atypical Neural Systems In Ds and Assoc...mentioning

confidence: 99%

Section: Psychedelic Drugs: Possible Brain Mechanismsmentioning

confidence: 99%

Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Pasculli,

Busan,

Jackson

et al. 2024

Front. Hum. Neurosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 The World Health Organization underscores the significance of anxiety disorders by ranking them as the sixth leading contributor to global disability, establishing it as a pressing health and wellness concern that demands attention. 4 Regrettably, the existing repertoire of anxiolytic medications faces challenges in adequately addressing the needs of the extensive population affected by anxiety disorders. 5 Benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) antidepressants are the primary drugs employed clinically for the treatment of anxiety disorders.…”

Section: Introductionmentioning

confidence: 99%